NASDAQ:GNPX Genprex (GNPX) Stock Price, News & Analysis → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free GNPX Stock Alerts $2.12 -0.08 (-3.64%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$2.12▼$2.2750-Day Range$2.12▼$3.1152-Week Range$2.09▼$42.40Volume27,598 shsAverage Volume35,342 shsMarket Capitalization$4.45 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Genprex alerts: Email Address Genprex MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside371.7% Upside$10.00 Price TargetShort InterestHealthy1.91% of Float Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment1.59Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.70) to ($2.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.60 out of 5 stars 3.5 Analyst's Opinion Consensus RatingGenprex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenprex has only been the subject of 1 research reports in the past 90 days.Read more about Genprex's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.91% of the float of Genprex has been sold short.Short Interest Ratio / Days to CoverGenprex has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genprex has recently decreased by 21.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenprex does not currently pay a dividend.Dividend GrowthGenprex does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGenprex has received a 75.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Genprex is -0.78. Previous Next 3.1 News and Social Media Coverage News SentimentGenprex has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Genprex this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for GNPX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genprex insiders have not sold or bought any company stock.Percentage Held by Insiders11.54% of the stock of Genprex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.05% of the stock of Genprex is held by institutions.Read more about Genprex's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Genprex are expected to grow in the coming year, from ($5.70) to ($2.71) per share.Price to Book Value per Share RatioGenprex has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Genprex's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyObama’s Forever Term [exposed]Over a decade ago, I tried to warn you... Because the same forces are once again brewing… and what’s coming next will forever reshape everything you think you know about America. Start streaming it now at no cost here About Genprex Stock (NASDAQ:GNPX)Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Read More GNPX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNPX Stock News HeadlinesMay 20, 2024 | msn.comGNPX Stock Earnings: Genprex Beats EPS for Q1 2024May 19, 2024 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Genprex (NASDAQ:GNPX)May 15, 2024 | markets.businessinsider.comGenprex’s Promising Clinical Trials and Leadership Drive Buy RatingMay 14, 2024 | prnewswire.comGenprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerMay 13, 2024 | markets.businessinsider.comGenprex Appoints Toscano As ChairmanMay 13, 2024 | prnewswire.comGenprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of DirectorsMay 9, 2024 | finanznachrichten.deGenprex, Inc.: Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerMay 8, 2024 | marketwatch.comGenprex Co-Founder, CEO Rodney Varner Dies of CancerMay 8, 2024 | prnewswire.comGenprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerMay 1, 2024 | prnewswire.comGenprex to Present and Participate at Upcoming May Investor and Industry ConferencesApril 9, 2024 | finance.yahoo.comGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingApril 9, 2024 | prnewswire.comGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingApril 3, 2024 | markets.businessinsider.comGenprex Expands Trial Sites For Reqorsa Therapy-Tecentriq Trial In Small Cell Lung Cancer; Stock UpApril 3, 2024 | prnewswire.comGenprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerApril 2, 2024 | markets.businessinsider.comGenprex: Collaborators Report Positive Preclinical Data With NPRL2 Gene TherapyApril 2, 2024 | prnewswire.comGenprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery SystemMarch 22, 2024 | prnewswire.comGenprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 21, 2024 | marketwatch.comGenprex Shares Drop 12% on Latest Stock Offering to Get Proceeds of $5.8MMarch 20, 2024 | marketwatch.comGenprex Shares Hit 52-Week Low After Direct Offering PricesMarch 19, 2024 | prnewswire.comGenprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 19, 2024 | finanznachrichten.deGenprex, Inc.: Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 19, 2024 | prnewswire.comGenprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 12, 2024 | markets.businessinsider.comGenprex Granted Korean Patent For Reqorsa Therapy With Anti-PD-1, PD-L1 AntibodiesMarch 12, 2024 | finance.yahoo.comGenprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat CancersMarch 9, 2024 | theglobeandmail.comGenprex (NASDAQ: GNPX) Preclinical Data to be Presented at AACR Annual MeetingSee More Headlines Receive GNPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2019Today5/28/2024Next Earnings (Estimated)8/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GNPX CUSIPN/A CIK1595248 Webwww.genprex.com Phone(877) 774-4679FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+371.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-272.65% Return on Assets-198.07% Debt Debt-to-Equity RatioN/A Current Ratio2.42 Quick Ratio2.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.99 per share Price / Book0.42Miscellaneous Outstanding Shares2,100,000Free Float1,857,000Market Cap$4.45 million OptionableOptionable Beta-0.54 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Mark S. Berger M.D. (Age 69)Chief Medical Officer Comp: $528.16kMr. David M. SchlossSenior Vice President of Human ResourcesMr. Thomas C. Gallagher Esq.Senior Vice President of Intellectual Property & LicensingDr. Suzanne Thornton-JonesSenior Vice President of Regulatory Affairs & QualityKey CompetitorsAlaunos TherapeuticsNASDAQ:TCRTKALA BIONASDAQ:KALAAytu BioPharmaNASDAQ:AYTUTalpheraNASDAQ:TLPHGlycoMimeticsNASDAQ:GLYCView All Competitors GNPX Stock Analysis - Frequently Asked Questions Should I buy or sell Genprex stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNPX shares. View GNPX analyst ratings or view top-rated stocks. What is Genprex's stock price target for 2024? 1 Wall Street research analysts have issued 12 month target prices for Genprex's stock. Their GNPX share price targets range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 371.7% from the stock's current price. View analysts price targets for GNPX or view top-rated stocks among Wall Street analysts. How have GNPX shares performed in 2024? Genprex's stock was trading at $9.20 at the beginning of 2024. Since then, GNPX stock has decreased by 77.0% and is now trading at $2.12. View the best growth stocks for 2024 here. Are investors shorting Genprex? Genprex saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 39,400 shares, a decline of 21.2% from the April 30th total of 50,000 shares. Based on an average daily trading volume, of 52,200 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.9% of the company's stock are sold short. View Genprex's Short Interest. When is Genprex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 19th 2024. View our GNPX earnings forecast. How were Genprex's earnings last quarter? Genprex, Inc. (NASDAQ:GNPX) announced its earnings results on Monday, April, 1st. The company reported ($9.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.40) by $3.80. When did Genprex's stock split? Shares of Genprex reverse split on the morning of Friday, February 2nd 2024. The 1-40 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Genprex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), iBio (IBIO) and Advanced Micro Devices (AMD). How do I buy shares of Genprex? Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GNPX) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsBiden replacement revealed?Paradigm PressTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
